Ballentine Partners, LLC Cure Vac N.V. Transaction History
Ballentine Partners, LLC
- $5.81 Billion
- Q4 2024
A detailed history of Ballentine Partners, LLC transactions in Cure Vac N.V. stock. As of the latest transaction made, Ballentine Partners, LLC holds 17,363 shares of CVAC stock, worth $50,179. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,363
Previous 22,755
23.7%
Holding current value
$50,179
Previous $66,000
10.61%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding CVAC
# of Institutions
86Shares Held
10.5MCall Options Held
75.5KPut Options Held
33.5K-
Black Rock Inc. New York, NY2.25MShares$6.51 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.65MShares$4.76 Million0.0% of portfolio
-
Bill & Melinda Gates Foundation Seattle, WA1.57MShares$4.53 Million10.6% of portfolio
-
Ubs Group Ag577KShares$1.67 Million0.0% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL500KShares$1.45 Million0.01% of portfolio
About CureVac N.V.
- Ticker CVAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,467,008
- Market Cap $542M
- Description
- CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...